FDA approves Roche ’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Evrysdi ™ (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older.

https://www.roche.com/media/releases/med-cor-2020-08-10b.htm

Source: Roche Media News - August 10, 2020 Category: Pharmaceuticals Source Type: news

More News: Children | Food and Drug Administration (FDA) | Pharmaceuticals | Spinal Muscular Atrophy